A randomized Phase II Study of Bevacizumab in Combination with Docetaxel or S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer Previously Treated with Platinum based Chemotherapy.

Trial Profile

A randomized Phase II Study of Bevacizumab in Combination with Docetaxel or S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer Previously Treated with Platinum based Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel; Gimeracil/oteracil/tegafur
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2015 Status changed from active, no longer recruiting to completed according to results published in the Lung Cancer.
    • 28 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 20 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top